Financial Review: ADM Tronics Unlimited (OTCMKTS:ADMT) & Bluejay Diagnostics (NASDAQ:BJDX)

ADM Tronics Unlimited (OTCMKTS:ADMT) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Profitability

This table compares ADM Tronics Unlimited and Bluejay Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ADM Tronics Unlimited	-0.20%	-0.85%	-0.32%
Bluejay Diagnostics	N/A	-144.27%	-115.00%

Analyst Recommendations

This is a summary of current ratings for ADM Tronics Unlimited and Bluejay Diagnostics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADM Tronics Unlimited	0	0	0	0	0.00
Bluejay Diagnostics	1	0	0	0	1.00

Insider & Institutional Ownership

18.5% of Bluejay Diagnostics shares are owned by institutional investors. 73.0% of ADM Tronics Unlimited shares are owned by insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

ADM Tronics Unlimited has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, Bluejay Diagnostics has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.

Earnings & Valuation

This table compares ADM Tronics Unlimited and Bluejay Diagnostics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADM Tronics Unlimited	$3.20 million	1.06	-$120,000.00	N/A	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85 million	($11.63)	-0.10

ADM Tronics Unlimited has higher revenue and earnings than Bluejay Diagnostics.

Summary

ADM Tronics Unlimited beats Bluejay Diagnostics on 5 of the 9 factors compared between the two stocks.

About ADM Tronics Unlimited

ADM Tronics Unlimited, Inc., through its subsidiaries, develops, manufactures, and sells electronics for non-invasive medical and other applications in the United States, Australia, Asia, and Europe. It operates through Chemical, Electronics, and Engineering segments. The company offers proprietary devices for use in diagnostics and therapeutics of humans and animals; and electronic controllers for spas and hot tubs. In addition, the company provides water-based primers and adhesives; water-based coatings and resins; water-based chemical additives; and anti-static conductive paints, coatings, and other products. Further, it offers water-based, adhesive and related topical formulations for use in maxillofacial prosthetic medical applications; and for professional makeup applications primarily for film, TV, and theatrical productions. Additionally, the company provides research, development, regulatory, and engineering services for the design, development, and manufacturing of medical devices, electronics, and other technologies and products, as well as medical electronic therapeutic technology. ADM Tronics Unlimited, Inc. was incorporated in 1969 and is headquartered in Northvale, New Jersey.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.